

Henry Ford Health

Henry Ford Health Scholarly Commons

Hospital Medicine Articles

Hospital Medicine

4-11-2022

Association of adding antiplatelet therapy to warfarin for management of venous thromboembolism with bleeding and other adverse events

Melinda Song

Brian Haymart

Xiaowen Kong

Mona Ali

Scott Kaatz

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/hospitalmedicine_articles

Authors

Melinda Song, Brian Haymart, Xiaowen Kong, Mona Ali, Scott Kaatz, Jay Kozlowski, Gregory D. Krol, Jordan Schaefer, James B. Froehlich, and Geoffrey D. Barnes

Association of adding antiplatelet therapy to warfarin for management of venous thromboembolism with bleeding and other adverse events

Vascular Medicine

1–3

© The Author(s) 2022

Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/1358863X221089333

journals.sagepub.com/home/vmj



Melinda Song¹ , Brian Haymart¹, Xiaowen Kong¹, Mona Ali² , Scott Kaatz³, Jay Kozlowski⁴, Gregory Krol³, Jordan Schaefer⁵, James B Froehlich¹ and Geoffrey D Barnes¹ 

Keywords

anticoagulation, anti-platelet therapy, anti-thrombotic therapy, bleeding, thrombosis, venous thromboembolism (VTE)

Clinical evidence regarding combination anticoagulant–antiplatelet therapy has largely focused on atrial fibrillation (AF) as the primary indication for anticoagulation. Expert recommendations from the American College of Cardiology (ACC) discourage the use of so-called ‘triple therapy’, that is, anticoagulation and dual antiplatelet therapy (aspirin and a P2Y₁₂ inhibitor), in patients on preexisting antiplatelet therapy who develop a new venous thromboembolism (VTE).¹ However, this guidance is extrapolated from evidence in AF without robust data in the VTE population, which has distinct demographics, comorbidities, and time-varying risk of recurrent thrombosis.² To address this gap, we explored a multicenter cohort of patients initiated on warfarin therapy for management of VTE. Our study aimed to evaluate the frequency and outcomes of antiplatelet therapy in addition to warfarin for patients with VTE.

We retrospectively analyzed adult patients in the Blue Cross Blue Shield-sponsored Michigan Anticoagulation Quality Improvement Initiative (MAQI²) registry who were newly initiated on warfarin therapy for VTE and entered in the registry between April 1, 2010 and October 31, 2020.^{3,4} Patients with a history of atrial fibrillation/flutter, heart valve replacement, and/or antiphospholipid antibody syndrome were excluded. Patient data were abstracted from the time of enrollment through the earliest of either the first adverse event, discontinuation of warfarin, or last follow-up before October 31, 2020. Patient characteristics were assessed at enrollment, while adverse events were assessed at each follow-up visit. Adjusted associations between number of antiplatelets and event outcomes were examined using Cox proportional hazards.

Of the 2918 patients initiating warfarin for treatment of VTE, 1333 (45.7%) were men with a mean (SD) age of 61.0 (16.4) years. During the study period, 820 patients (28.1%) received warfarin plus one or more antiplatelet medications, compared to 2098 (71.9%) who received

warfarin monotherapy (online Supplementary Table 1). Patients on combination warfarin and antiplatelet therapy had a higher incidence of documented coronary artery disease, prior myocardial infarction, and coronary revascularization. Compared to the warfarin monotherapy group, the combination warfarin–antiplatelet group had a higher average RIETE bleed score (2.5 vs 2.0, $p < 0.001$).^{5,6} Aspirin monotherapy was the most common antiplatelet regimen (83.4%), followed by dual antiplatelet therapy (11.0%) and P2Y₁₂ inhibitor monotherapy (5.1%).

The warfarin monotherapy reference group experienced 3.3 thrombotic events per 100-patient-years, compared to warfarin plus single antiplatelet (2.7 per 100-patient-years, $p = 0.190$) or warfarin plus dual antiplatelet (2.2 per 100-patient-years, $p = 0.773$; Figure 1). The warfarin monotherapy reference group experienced 20.0 overall bleeding events per 100-patient-years, compared to warfarin plus single antiplatelet (24.7 per 100-patient-years, $p = 0.013$) or warfarin plus dual antiplatelet (58.9 per 100-patient-years, $p < 0.001$; Figure 1).

After controlling for age, gender, race, provoked status of VTE, and RIETE score, use of one antiplatelet

¹Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA

²Department of Heart and Vascular Services, Beaumont Hospital, Royal Oak, MI, USA

³Division of Hospital Medicine, Henry Ford Hospital, Detroit, MI, USA

⁴Department of Cardiovascular Medicine, DMC Huron Valley-Sinai Hospital, Commerce, MI, USA

⁵Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA

Corresponding author:

Geoffrey D Barnes, Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, 2800 Plymouth Rd, Building 14-Room G214, Ann Arbor, MI 48109-2800, USA.
Email: gbarnes@umich.edu




Figure 1. Rates of thrombotic, bleeding, and associated events in patients with VTE with no, one, or two antiplatelet medications in addition to warfarin.

A Poisson test was used to calculate p -values, in comparison to the warfarin monotherapy reference group; 'ns' denotes $p > 0.05$, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

ER, emergency room; FFP, fresh frozen plasma; ISTH, International Society on Thrombosis and Haemostasis; RBC, red blood cell; VTE, venous thromboembolism.

medication (hazard ratio (HR) 1.21; 95% CI, 1.02–1.43) and use of two antiplatelet medications (HR 2.37; 95% CI, 1.65–3.39) were associated with increased overall bleeding. When examining major bleeding as defined by the International Society on Thrombosis and Haemostasis as the outcome variable,⁷ use of one antiplatelet medication (HR 1.37; 95% CI, 0.93–2.02) and use of two antiplatelet medications (HR 1.58; 95% CI, 0.57–4.36) were not significant. With regards to nonmajor bleeding, use of one antiplatelet medication (HR 1.20; 95% CI, 0.99–1.45) was not significant whereas use of two antiplatelet medications was significant (HR 2.53; 95% CI, 1.71–3.75).

In this large, registry-based cohort study of patients followed by anticoagulation clinics while receiving warfarin for VTE, 28.1% of patients received either one or two additional antiplatelet medications. Compared to warfarin monotherapy, combination warfarin–antiplatelet therapy in patients with VTE was associated with increased bleeding and similar rates of thrombosis. This differential bleeding risk is largely driven by nonmajor bleeds.

Our investigation is one of a few dedicated VTE studies examining antithrombotic management in an unselected, practice-based setting. These results provide additional evidence to support the recent 2021 ACC guidelines discouraging 'triple therapy' regimens in patients with VTE and atherosclerotic cardiovascular disease, due to unnecessary bleeding risk.¹ Moreover, antiplatelet therapy has been identified as one of the few potentially modifiable bleeding risk factors in patients with VTE.⁶ Our findings are also consistent with research demonstrating a significantly higher rate of nonmajor bleeding, in particular among patients taking combination aspirin–direct oral anticoagulant (DOAC) therapy compared to DOAC monotherapy.⁸

Limitations of this study include those inherent to registry data, including the potential for unmeasured confounding. It is unknown how these findings generalize to patients

receiving DOACs, though these results are consistent with a meta-analysis of six randomized trials that demonstrated an increased risk of bleeding and similar risk of thrombosis in patients with VTE treated with combination DOAC–antiplatelet therapy.⁹

In conclusion, use of combination anticoagulant–antiplatelet therapy among patients with VTE is common and associated with higher risk of bleeding. Prospective studies to validate the safety and efficacy of antiplatelet reduction for patients receiving anticoagulation for VTE would strengthen expert management recommendations.

Declaration of conflicting interests

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: SK serves as a consultant for Janssen, Pfizer, Bristol Myers Squibb, PhaseBio, and Gilead. JBF serves as a consultant for Janssen, Merck, and Novartis. GDB serves as a consultant for Janssen, Pfizer, Bristol Myers Squibb, and Acelis Connected Health. All other authors have no conflicts of interest to disclose.


Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Melinda Song  <https://orcid.org/0000-0003-1727-0165>

Mona Ali  <https://orcid.org/0000-0003-2416-6702>

Geoffrey D Barnes  <https://orcid.org/0000-0002-6532-8440>

Supplementary material

The supplementary material is available online with the article.

References

1. Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC Expert Consensus Decision Pathway for anticoagulant and

- antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: A report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol* 2021; 77: 629–658.
2. Riva L, Ageno W, Di Pasquale G, et al. Antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent: The case of venous thromboembolism. *Int J Cardiol* 2018; 269: 75–79.
 3. Schaefer JK, Li Y, Gu X, et al. Association of adding aspirin to warfarin therapy without an apparent indication with bleeding and other adverse events. *JAMA Intern Med* 2019; 179: 533–541.
 4. Kurlander JE, Gu X, Scheiman JM, et al. Missed opportunities to prevent upper GI hemorrhage: The experience of the Michigan Anticoagulation Quality Improvement Initiative. *Vasc Med* 2019; 24: 153–155.
 5. Guijarro R, Montes J, Sanromán C, et al. Venous thromboembolism in Spain. Comparison between an administrative database and the RIETE registry. *Eur J Intern Med* 2008; 19: 443–446.
 6. Klok FA, Huisman MV. How I assess and manage the risk of bleeding in patients treated for venous thromboembolism. *Blood* 2020; 135: 724–734.
 7. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost* 2005; 3: 692–694.
 8. Schaefer JK, Erickson J, Li Y, et al. Adverse events associated with the addition of aspirin to direct oral anticoagulant therapy without a clear indication. *JAMA Intern Med* 2021; 181: 817–824.
 9. Valeriani E, Porreca E, Weitz JI, et al. Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. *J Thromb Haemost* 2020; 18: 1661–1671.